GNPX logo

Genprex, Inc.

GNPX
Healthcare|Biotechnology|US
$2.07
-0.03 (-1.43%)
DCF Value
$168.10
Tangible Book / Share
$31.27
Cash / Share
$32.03
Next Earnings Report
Dec 2, 2026
EPS est. -$6160.00
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Jun 5, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (2)

Dec 2027
Est. completion
P1P2Small Cell Lung Cancer Extensive Stage
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT05703971n=62
Mar 2028
Est. completion
P1P2Carcinoma, Non-Small Cell Lung
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
NCT04486833n=158

Recent Press Releases

Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
Nov 5, 2026 · PRNewsWire
Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
Nov 4, 2026 · PRNewsWire
Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
Oct 28, 2026 · PRNewsWire
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging
Oct 21, 2026 · PRNewsWire
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026 · PRNewsWire
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
Aug 18, 2026 · PRNewsWire

SEC Filings (94)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 20268-KMaterial eventDocumentIndex
Nov 4, 20268-KMaterial eventDocumentIndex
Oct 28, 20268-KMaterial eventDocumentIndex
Oct 21, 20268-KMaterial eventDocumentIndex
Aug 18, 20268-KMaterial eventDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Aug 3, 20268-KMaterial eventDocumentIndex
Jul 30, 20268-KMaterial eventDocumentIndex
Jul 14, 20268-KMaterial eventDocumentIndex
Jun 26, 2026S-8Employee stock planDocumentIndex
Jun 22, 20268-KMaterial eventDocumentIndex
Jun 18, 20268-KMaterial eventDocumentIndex
Jun 12, 20268-KMaterial eventDocumentIndex
Jun 5, 2026S-3Shelf registrationDocumentIndex
May 26, 20268-KMaterial eventDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 11, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 29, 2026ARSAnnual report to holdersDocumentIndex
Apr 29, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 28, 20268-KMaterial eventDocumentIndex
Apr 21, 20268-KMaterial eventDocumentIndex
Apr 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 30, 202610-KAnnual reportDocumentIndex
Mar 18, 20268-KMaterial eventDocumentIndex
Feb 23, 20268-KMaterial eventDocumentIndex
Feb 11, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 10, 20268-KMaterial eventDocumentIndex
Jan 9, 20268-KMaterial eventDocumentIndex
Jan 9, 2026S-8Employee stock planDocumentIndex
Jan 7, 20268-KMaterial eventDocumentIndex
Jan 6, 20268-KMaterial eventDocumentIndex
Dec 23, 20258-KMaterial eventDocumentIndex
Dec 12, 2025EFFECTDocumentIndex
Dec 12, 2025424B3Offering prospectusDocumentIndex
Nov 26, 2025S-1/AIPO / offering registrationDocumentIndex
Nov 26, 20258-KMaterial eventDocumentIndex
Nov 21, 2025S-1IPO / offering registrationDocumentIndex